Chronic liver disease has emerged as the leading cause of non-HIV-related mortality among women with HIV, driven by a high prevalence of metabolic dysfunction-associated steatotic liver disease and accelerated fibrogenesis. A recent all-women U.S. cohort data analysis published by TheBodyPro and reviewed in Current Opinion in HIV and AIDS reveals that steatotic liver disease affects 47% of women regardless of HIV status, with body mass index and diabetes serving as major predictors.
Prevalence and Risk Factors in U.S. Women
The data from the all-women U.S. cohort demonstrate that modern-day steatotic liver disease is extremely common even outside of viral hepatitis coinfection. Body mass index and diabetes stand out as major predictors for the condition across the board. However, the presence of HIV complicates this physiological picture significantly.
Among women with steatotic liver disease, researchers found that HIV was associated with a 48% greater adjusted odds of clinically significant fibrosis. This elevated risk requires clinicians to look beyond standard metabolic markers when evaluating patients.
Pathophysiology of Liver Injury and Fibrogenesis
In the current era of effective antiretroviral therapy, viral hepatitis-related liver disease has decreased in prevalence. At the same time, alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease have become much more common. Several distinct mechanisms cause accelerated fibrogenesis in women with HIV.
These mechanisms include direct cytopathic effects from HIV, antiretroviral therapy itself, gastrointestinal barrier impairments, and microbiome alterations. Furthermore, the menopausal transition acts as a critical period in which women with HIV develop a profibrogenic state that is further exacerbated by HIV-associated estrogen deficiency.
Clinical Management and Future Interventions
Clinicians treating patients with HIV must assess fibrosis risk alongside metabolic factors. Medical providers should resist assumptions that blame antiretroviral therapy entirely for liver complications, or jump to the conclusion that simple steatosis indicates significant liver disease on its own.
Therapeutic options are evolving to address these challenges. Glucagon-like peptide-1 receptor agonists hold promise in reversing hepatic steatosis among women with HIV. At the same time, higher rates of hazardous alcohol use and psychiatric comorbidities in women with HIV—compared to men with the virus—increase the risk of alcohol- and viral hepatitis-related liver disease.
Frequently Asked Questions
What makes women with HIV more vulnerable to advanced liver disease?
Biological sex differences, social marginalization, and HIV infection itself create unique challenges to achieving optimal liver disease care. Additionally, HIV-associated estrogen deficiency during the menopausal transition exacerbates a profibrogenic state.
How does alcohol use impact liver disease risk in this population?
Women with HIV experience higher rates of hazardous alcohol use and psychiatric comorbidities compared to men with HIV. This combination increases the overall risk of developing alcohol-related and viral hepatitis-related liver damage.
What is the role of newer medications in treating steatotic liver disease in patients with HIV?
Glucagon-like peptide-1 use holds promise in reversing hepatic steatosis in women with HIV, offering a potential therapeutic pathway as researchers continue investigating targeted interventions.
Keep reading